MedPath

Lutetium Lu-177 vipivotide tetraxetan

Generic Name
Lutetium Lu-177 vipivotide tetraxetan
Brand Names
Pluvicto
Drug Type
Small Molecule
Chemical Formula
C49H68LuN9O16
CAS Number
1703749-62-5
Unique Ingredient Identifier
G6UF363ECX
Background

Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, lutetium Lu-177, linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.

Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended lutetium Lu-177 vipivotide tetraxetan be granted marketing authorization for the treatment of prostate cancer. In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.

Indication

Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Associated Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Associated Therapies
-
Clinical Trials
Related News
singularityhub.com
·

Four Clinical Trials We're Watching That Could Change Medicine in 2025

Recent clinical trials highlight advancements in medicine, including Ozempic and Wegovy's potential beyond weight loss, lenacapavir's HIV prevention, base editing for sickle cell disease, Pluvicto for prostate cancer, CBD for psychosis, and personalized breast cancer screening. These developments promise significant impacts on healthcare.

Related Clinical Trials:

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
targetedonc.com
·

Epigenomic Platform Enhances Access to PSMA-Based Prostate Cancer Therapies

A new epigenomic liquid biopsy platform could bypass the need for PSMA PET scans, improving access to PSMA-based therapies for prostate cancer patients, especially in underserved communities. Presented at the 2024 ESMO Congress, it accurately detects PSMA expression from blood, potentially predicting therapy outcomes.
urologytimes.com
·

Agreement reached for public reimbursement of Pluvicto in Canada

Novartis secured public reimbursement of lutetium-177 vipivotide tetraxetan (Pluvicto) for PSMA-positive mCRPC patients in Canada. Pluvicto, approved by Health Canada in 2022 and the US FDA in 2022, offers hope for patients with advanced prostate cancer. The therapy still needs to be added to provincial formularies for patient access.

Related Clinical Trials:

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
hitconsultant.net
·

Nucs AI Secures $3.5M to Advance AI-Powered Prostate Cancer Diagnostics

Nucs AI, using AI in precision medicine for prostate cancer, closed a $3.5M seed round to build its platform and seek FDA clearance. Their tools, DeepPSMA and SelectPSMA, enhance PSMA-PET/CT imaging and predict patient response to PSMA-targeted radiopharmaceuticals, aiming to improve prostate cancer care.
biopharmadive.com
·

Janux impresses Wall Street with new prostate cancer drug results

Janux Therapeutics' shares surged 75% after Phase 1a study results for JANX007, a T cell engager for metastatic, castration-resistant prostate cancer, showed promising efficacy and safety, with 16 patients achieving at least a 50% reduction in prostate-specific antigens.
markets.ft.com
·

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by ...

JANX007 showed high PSA response rates, deep PSA declines, and durable PSA responses in 5L mCRPC patients, supporting its clinical development for pre-PLUVICTO® 2L/3L patients. JANX007 was well-tolerated with CRS and TRAEs primarily limited to cycle 1 and grades 1 and 2, with no maximum tolerable dose reached. Janux Therapeutics hosted a virtual investor event to discuss these findings.
cbc.ca
·

B.C. man calls for federal government to cover costly, life-saving cancer treatment

Pluvicto, a new prostate cancer treatment using lutetium-177, costs $27,000 per dose, totaling $135,000 for an average five-dose treatment. The pan-Canadian Pharmaceutical Alliance (pCPA) ended negotiations with Novartis, leaving patients to fund the treatment themselves. Health Canada approved Pluvicto in 2022, but coverage is unavailable in B.C. without third-party insurance or private payment. Patients and advocates call for renewed negotiations to make the treatment accessible.
finance.yahoo.com
·

Global Cancer Peptide Drugs Market Cancer Peptide Therapeutics Clinical Trials

Global peptide cancer drug market to exceed US$ 18 billion by 2030, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, with major players like Novartis and emerging firms driving innovation.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy